Now with the delay of GTA 6 to November 2026 and potentially another delay to 2027, we could actually be getting PP405 before GTA 6. Chat 11/9/2025
A potential baldness cure, possibly PP405, might be available before the release of GTA 6, which is delayed to 2026 or 2027. There is skepticism about the effectiveness and release timeline of PP405.
View this post in the Community →
Similar Community Posts Join
6 / 6 resultscommunity Phase 3 Study for PP405 officially posted
PP405 is in a phase 3 trial for hair loss treatment, with the study expected to run until June 2028. Minoxidil and finasteride remain key treatments, with hopes for PP405 to offer a new mechanism of action.
community Pelage have made a new post about PP405
PP405 aims to reactivate hair follicle stem cells to promote hair growth, but its effectiveness is debated. Some users are skeptical, citing past failures of similar treatments and questioning the company's claims.
community Why PP405 may not be dead just yet
PP405 shows promise in reactivating dormant hair follicles, with early trials indicating some success, but it is not yet a proven treatment for hair loss. Users are advised to be cautious with unverified versions, and further research is needed to confirm its effectiveness compared to treatments like minoxidil and finasteride.
community PP405 (JXL069) Is Confirmed: Here’s Everything I’ve Learned After a Year of Testing
JXL069, also known as PP405, did not lead to hair regrowth after a year of testing. The lack of results may be due to formulation issues, leading to a final attempt with an improved vehicle.
community Why you can still look forward to PP405 and JXL-069
PP405 and JXL-069 are the same compound, but users experienced no results due to flawed application methods. The topical gel formulation of PP405 is designed to target hair follicle stem cells effectively, unlike liquid solutions that fail to penetrate deeply.
community If PP405 doesn't work then why would Pelage continue with trials?
PP405 is still undergoing trials despite skepticism about its effectiveness. Some believe it shows potential for hair regrowth, possibly in combination with other treatments like minoxidil or finasteride, while others are doubtful due to past disappointments with similar products.
Related Research
6 / 6 resultsresearch PP405 in Alopecia: An Emerging Molecule worth Investigating
In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.
research Diagnostic Comparison: SH‑1 Molecule vs PP405 — Safety Profiles in Hair Science
This infographic compares the safety profiles of SH‑1, a cosmetic ingredient, which showed no systemic absorption, and PP405, an investigational drug with dose-dependent systemic uptake and potential threshold breaches, highlighting differences in safety between cosmetic and investigational substances according to this report.
research LB1045 Inhibition of pyruvate oxidation activates human hair follicle stem cells ex vivo
PP405 may help hair growth by activating hair follicle stem cells.
research Review of the 2024 American Academy of Dermatology (AAD) Annual Meeting
This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.
research Use of Vitamins and Minerals in the Treatment of Hair Loss: A Cross-Sectional Survey among Dermatologists in Saudi Arabia
This study found that a majority of dermatologists in Saudi Arabia believe in using vitamins and minerals to treat hair loss but emphasized the need for more research to confirm their effectiveness.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.